Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 31st total of 5,060,000 shares. Based on an average trading volume of 2,120,000 shares, the short-interest ratio is currently 2.6 days.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fullcircle Wealth LLC bought a new position in Adaptimmune Therapeutics in the 3rd quarter valued at approximately $33,000. Vontobel Holding Ltd. lifted its position in Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 30,000 shares in the last quarter. GSA Capital Partners LLP bought a new position in Adaptimmune Therapeutics in the 3rd quarter valued at approximately $95,000. Virtu Financial LLC raised its stake in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 21,769 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 98,581 shares during the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP opened at $0.59 on Monday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average price is $0.62 and its 200-day moving average price is $0.86. Adaptimmune Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.05. The stock has a market cap of $150.97 million, a P/E ratio of -2.68 and a beta of 2.24.

Analyst Upgrades and Downgrades

ADAP has been the topic of a number of research analyst reports. Guggenheim reduced their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. StockNews.com downgraded Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. HC Wainwright reduced their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Mizuho dropped their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $2.79.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.